Eli Lilly and market cap LLY
Share price times shares outstanding: what the whole company sells for, since 2009.
- Today, Oct 23, 2026
- $1.2T
- Highest close in our data
- $1.2T
- Oct 2026
Eli Lilly and is worth $1.2T at the close on Oct 23, 2026, at $1,273.46 a share.
That is up 53% over the last year and up 392% over five years.
Its highest close in our data was $1.2T in Oct 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $1.2T | $828.5B | $1.2T | +18% |
| 2025 | $1T | $592.2B | $1T | +37% |
| 2024 | $743.5B | $587.2B | $912.4B | +34% |
| 2023 | $553.4B | $299.4B | $578.3B | +59% |
| 2022 | $347.6B | $225.5B | $356.1B | +32% |
| 2021 | $264.2B | $159.2B | $264.2B | +64% |
| 2020 | $161.5B | $117.1B | $164B | +28% |
| 2019 | $126.3B | $103.7B | $134.4B | +4% |
| 2018 | $121B | $81.9B | $125.7B | +30% |
| 2017 | $93B | $83.2B | $96B | +15% |
| 2016 | $81.2B | $74.7B | $91.5B | −13% |
| 2015 | $93.4B | $76B | $98.1B | +19% |
| 2014 | $78.4B | $57.6B | $80.6B | +36% |
| 2013 | $57.7B | $54.5B | $65.2B | +2% |
| 2012 | $56.4B | $45.2B | $61.3B | +17% |
| 2011 | $48.1B | $39.5B | $48.2B | +19% |
| 2010 | $40.4B | $37.3B | $43.5B | −2% |
| 2009 | $41B | $37.4B | $43B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Eli Lilly and's size, closest first, today.
| Company | Market cap |
|---|---|
| LLYEli Lilly and | $1.2T |
| JNJJohnson & Johnson | $635.8B |
| ABBVAbbVie | $504.8B |
| MRKMerck | $358.4B |
| AMGNAmgen | $237.5B |
| GILDGilead Sciences | $193.5B |
| PFEPfizer | $171.2B |
| BMYBristol-Myers Squibb | $125.6B |
| Peer median | $237.5B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Eli Lilly and
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.